The trial is designed to include an enriched population of patients with KRAS and NRAS wild-type rectal cancer due to evidence of lack of benefit from anti-EGFR strategies in KRAS or NRAS mutated colorectal tumors. The gene discussed is EGFR; the disease is rectal cancer.